ReviewTaiwan journal of ophthalmology
Growth of indeterminate choroidal melanocytic tumors: Time to malignant transformation.
Review in Taiwan journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ocular oncology: Rare and amazing.Taiwan journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Indeterminate choroidal melanocytic tumors may exhibit growth under observation, but the clinical significance of early versus late growth remains unclear. In this review we aim to explore the temporal profile of growth to detect benign and malignant subsets. There was no specific set of tumor dimensions or characteristics applied for exclusion or inclusion except that all included tumors had to be described as indeterminate or suspicious nevus and observed for growth by the authors. Nine published studies (1977-2021) that included 8766 patients were reviewed. The primary outcomes were time to event (growth) and its correlation with the growth rate of small choroidal melanoma. The studies were largely retrospective and had differing inclusion criteria: largest basal diameter of 7.5-24 mm (mean, 14.83 mm) and maximum height of 2-6.7 mm (mean, 4.19 mm). Most defined growth by a change in height of >0.3 mm or base of >0.5. Among 8606 tumors followed, 478 (5.6%) showed growth over 5 years, with growth rates in individual studies ranging from 2% to 55% (mean: 19.0%). The highest event rate occurred in the 1st year (range: 0.7%-15%; mean: 6.5%), stabilizing to 0%-5% (mean: 1.5%) by year 5. The majority (range: 52%-83%; mean: 67%) were observed to grow in the initial 2 years (early growth). Over subsequent years (late growth), the proportion of growing tumors reduced and stabilized by years 4 and 5 to a mean of 6.1% and 8.3%, respectively. Time-to-event analysis indicates the heterogeneity of IMTs. Tumors growing in the first 2 years (early growth) may be melanoma in the evolution and their characteristics previously identified as the risk factors for growth may be interpreted as the factors predictive or diagnostic of small choroidal melanoma. In contrast, tumors demonstrating growth in subsequent years (late growth), after documented stability, may represent malignant transformation of a choroidal nevus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.